Search hospitals > New York > Rochester
University of Rochester
Claim this profileRochester, New York 14618
Global Leader in Skin Cancer
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Lymphoma
Conducts research for Cancer
Conducts research for Lung Cancer
1134 reported clinical trials
66 medical researchers
Summary
University of Rochester is a medical facility located in Rochester, New York. This center is recognized for care of Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lymphoma, Cancer, Lung Cancer and other specialties. University of Rochester is involved with conducting 1,134 clinical trials across 1,354 conditions. There are 66 research doctors associated with this hospital, such as Paul M. Barr, Yuhchyau Chen, Angela R. Girvin, and Craig A. Mullen.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
Philadelphia chromosome positive
Stage I
Top PIs
Paul M. BarrUniversity of Rochester6 years of reported clinical research
Expert in Skin Cancer
Expert in Lymphoma
85 reported clinical trials
166 drugs studied
Yuhchyau ChenUniversity of Rochester5 years of reported clinical research
Expert in Skin Cancer
Studies Lung Cancer
38 reported clinical trials
81 drugs studied
Angela R. GirvinUniversity of Rochester7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
30 reported clinical trials
70 drugs studied
Craig A. MullenUniversity of Rochester7 years of reported clinical research
Expert in Lymphoma
Expert in Non-Hodgkin's Lymphoma
22 reported clinical trials
52 drugs studied
Clinical Trials running at University of Rochester
Lung Cancer
Prostate Cancer
Breast Cancer
Multiple Myeloma
Skin Cancer
Ovarian Cancer
Lymphoma
Pancreatic Cancer
Stomach Cancer
Non-Small Cell Lung Cancer
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Rochester?
University of Rochester is a medical facility located in Rochester, New York. This center is recognized for care of Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lymphoma, Cancer, Lung Cancer and other specialties. University of Rochester is involved with conducting 1,134 clinical trials across 1,354 conditions. There are 66 research doctors associated with this hospital, such as Paul M. Barr, Yuhchyau Chen, Angela R. Girvin, and Craig A. Mullen.
Where is University of Rochester located?
The University of Rochester Medical Center is located at 601 Elmwood Ave, Rochester, NY 14620, on its campus. Multiple parking options are available, including a six-floor ramp garage connected to Strong Memorial Hospital, Golisano Children’s Hospital, and Wilmot Cancer Center.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the University of Rochester Medical Center, including Strong Memorial Hospital and Highland Hospital:
- Contact the Financial Assistance Officer at (585) 784-8889 or (800) 257-7049 for insurance verification, Medicaid assistance, community outreach, financial counseling, and case management.
- To apply, submit an application with four consecutive paystubs, Social Security income, pension information, unemployment or workers' compensation award letters, or other proof of household gross income to: Financial Assistance Officer, Strong Memorial Hospital, 601 Elmwood Avenue – Box 888, Rochester, NY 14642.
- For more details, visit Highland Hospital's financial assistance page or Strong Memorial Hospital's financial assistance page for guidelines and FAQs.
What insurance does University of Rochester accept?
The University of Rochester accepts a wide range of insurance plans, including but not limited to Aetna, Beacon Health Options, CIGNA, Excellus BlueCross and BlueShield, Fidelis Care, Humana, MVP Health Care, TRICARE, UnitedHealthcare, and Wellcare by Fidelis Care Medicare Plans. UR Medicine also contracts with most major health insurance carriers. Patients are advised to contact their insurance company to confirm access to health care services at UR Medicine locations.
What awards or recognition has University of Rochester received?
The University of Rochester Medical Center (URMC) is a leading institution in biomedical research, receiving over $1.3 billion in funding over the past five years. The UR CTSI offers seed funding for innovative clinical and translational research projects, with grants from $10,000 to $200,000. This initiative supports researchers at all career stages, promoting the advancement of medical science and the improvement of human health.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.